Business Description
LadRx Corp
NAICS : 325414
SIC : 2836
ISIN : US2328286081
Compare
Compare
Traded in other countries / regions
LADX.USACX5.Germany0I5R.UK IPO Date
1986-11-10Description
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LadRx Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -4.612 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -34.93 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 0.056 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.056 - 0.056 | ||
| Shares Outstanding (Mil) | 0.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LadRx Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LadRx Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-16 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 36 days | ||
| General meeting for 2025 | 2026-07-31 | In 16 days | ||
| Annual report for 2025 | 2026-07-21 | In 6 days | ||
| First quarter earnings results for 2025 | 2025-05-14 | 0.06 (+0.00%) | ||
| Annual report for 2024 | 2025-03-28 | 0.06 (+0.00%) | ||
| Virtual Life Science Investor Forum | 2025-03-13 15:00 | 0.06 (+0.00%) | ||
| Third quarter earnings results for 2024 | 2024-11-14 | 0.06 (+0.00%) | ||
| General meeting for 2024 | 2024-10-04 10:00 | 0.06 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-08-14 | 0.06 (+0.00%) |
Show
Entries
LadRx Corp Frequently Asked Questions
What is LadRx Corp(STU:CX5)'s stock price today?
The current price of STU:CX5 is €0.06. The 52 week high of STU:CX5 is €0.06 and 52 week low is €0.06.
When is next earnings date of LadRx Corp(STU:CX5)?
The next earnings date of LadRx Corp(STU:CX5) is 2026-08-20 Est..
Does LadRx Corp(STU:CX5) pay dividends? If so, how much?
LadRx Corp(STU:CX5) does not pay dividend.
Press Release
Articles on LadRx Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers